All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2023-08-07.
From the record
Innoviva, Inc.'s filings since 2017 show 3 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2023-08-07); an auditor change (8-K item 4.01, 2 times, the latest 2022-03-25) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+13.3% a year over 10 filed years; profitable in 10 of 10.
From the record
Innoviva, Inc.'s 10 filed years say what it did: revenue went from $134 million in fiscal 2016 to $411 million in fiscal 2025, up 13.3% a year; it rose in 7 of 9 years; the deepest fall was 21% from fiscal 2021 to fiscal 2023; net income was positive in 10 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count shrank 1.1% a year. 18% of cash flow returned. Insiders: 0 sales, 0 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Innoviva, Inc.'s diluted share count shrank about 1.1% a year, and dividends and buybacks returned about 18% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE 23%: 23¢ of profit per shareholder dollar. Leverage 28%: owes 28¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Innoviva, Inc. earned about 23 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 19 cents per dollar of everything the company owns. Leverage: it owed about 28 cents per dollar of assets, and net share issuance: its share count grew 7.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 26% of 315 in its family; net margin 65.9%.
From the record
Innoviva, Inc.'s standing among 315 graded names in its industry family: revenue of $411 million in fiscal 2025 ranks in the top 21% by size; a net margin of 65.9% ranks in the top 4%; revenue growth of 7.5% a year over the last 3 filed years ranks in the bottom 48% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 45% of 315 in its family for leadership; chief executive since 2026.
From the record
Innoviva, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Raifeld, Pavel (Chief Executive Officer, as filed), filing under that title since 2026-02-24, 9 months (bottom 11% of its family); the 8 officers and directors filing in the last fifteen months have been on the record a median of 7.4 years (top 24%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 8 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 49% of 273 in its family for room to expand.
From the record
Innoviva, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $551 million against debt of $258 million leaves 17.9% of its assets as net cash, bottom 36% of its family; cash from operations less capital spending is 47.6% of revenue (top 3%); a gross margin of 74.8% (top 41%); research spending of 7.4% of revenue (bottom 11%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 43% of 306 in its family for growth drivers.
From the record
Innoviva, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 7.5% a year over the last three filed years against 13.3% over all 10, slowing (bottom 42% of its family); the newest year grew 14.7% (top 42%); research spending grew -9.6% a year (bottom 32%); capital spending grew 156.5% a year (top 5%) (its annual reports). Innoviva, Inc. reported 6 product lines in fiscal 2025: Royalty at $236 million (57%), Xacduro at $74 million (18%), Giapreza at $74 million (18%), and 3 more; 3 of 5 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 31% of 233 in its family for expectations against reality.
From the record
Innoviva, Inc.'s newest year against its own record: revenue of $411 million in fiscal 2025 came in 10.2% above the $373 million its prior three years' pace pointed to (top 33% of its family); net income of $271 million against a prior three-year average of $139 million (top 17%); a net margin of 65.9% against 43% before (top 43%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made